Michael focuses his practice on intellectual property disputes and patent litigation. He has extensive experience litigating cases involving pharmaceutical compounds, biotechnology products, computer technology, and software. Michael has managed every stage of litigation, from complaint through trial. He is also a registered patent attorney and has represented clients in IPRs before the U.S. Patent and Trademark Office and in appeals before the Federal Circuit.
Michael has also published articles on the role of post-grant proceedings in U.S. patent disputes, which have appeared in the Journal of Intellectual Property Law and the Baylor Law Review. His publications have been cited by the Federal Circuit and in briefs before the U.S. Supreme Court.
Before joining Williams & Connolly, Michael clerked for Judge Todd M. Hughes of the U.S. Court of Appeals for the Federal Circuit. Michael graduated magna cum laude from the University of Michigan Law School in 2014, and holds a Master’s degree in Biomedical Engineering from Tulane University. As part of his graduate studies, Michael researched low-cost medical devices for use in rural and developing areas.
Representative Experience
Though all cases vary and none is predictive, Michael's experience includes:
- Counsel for Pfizer in patent infringement litigation brought by Moderna concerning Pfizer’s COVID-19 vaccine.
- Counsel for Google in a patent infringement action in the Eastern District of Virginia related to mobile device geolocation technology, obtained dismissal of all claims under section 101.
- Counsel for Pfizer in brand v. brand inter partes review proceedings involving gene therapy patents. The Patent Trial and Appeals Board issued three final written decisions in Pfizer’s favor.
- Counsel for numerous branded pharmaceutical companies in Hatch-Waxman cases against generic drug manufacturers, including litigation involving Pfizer’s Ibrance® and Inlyta® products; Eli Lilly’s Alimta® product; BeiGene’s Brukinsa® product; and Novartis’s Xiidra® product.